| S.NO | Uniprot ID | Protein Name | Sequence Length | SH3 Region | Mutation | Involvement of Repeats in Mutations |
| 1 | P15498 | Proto-oncogene vav | 845 | 529 529 C->R: Abolishes transforming activity 696 696 R->L: Loss of interaction with SYK | N | |
| 2 | Q8NFA2 | NADPH oxidase organizer 1 | 376 | 40 40 R->Q: Loss of ability to activate NOX1 associated with loss of lipid-binding and plasma membrane localization 202 202 W->R: Loss of ability to activate NOX3 and interact with CYBA 274 274 W->R: Induces interaction with NOXA1 in vitro 332 332 P->A: Loss of intramolecular interaction 334 334 R->A: Loss of intramolecular interaction | Y | |
| 3 | P62993 | Growth factor receptor-bound protein 2 | 217 | 49 49 P->L: Ineffective in DNA synthesis when associated with L-206 89 89 E->K: No effect on the interaction with SOS1 90 90 S->N: No effect on the interaction with SOS1 203 203 G->R: Ineffective in DNA synthesis 206 206 P->L: Abolishes interaction with SHB when associated with L-49 | Y | |
| 4 | O60504 | Vinexin | 671 | 649 649 W->F: Loss of SOS-binding ability 667 667 Y->V: Loss of SOS-binding ability | Y | |
| 5 | Q8TEC5 | E3 ubiquitin-protein ligase SH3RF2 | 729 | 643 643 V->G: Significant loss of interaction with PPP1CA when associated with G-645 645 645 F->G: Significant loss of interaction with PPP1CA when associated with G-643 | N | |
| 6 | P46108 | Adapter molecule crk | 304 | 150 150 D->K: Abolishes interaction with DOCK1 169 169 W->L: Abolishes interaction with DOCK5 | Y | |
| 7 | Q7Z6J0 | E3 ubiquitin-protein ligase SH3RF1 | 888 | 14 14 V->A: Loss of Ubl activity 28 28 C->A: Significant reduction in autoubiquitination when associated with A-30 30 30 H->A: Significant reduction in autoubiquitination when associated with A-28 304 304 S->A: Decreased level of phosphorylation and no change in the ability to induce apoptosis 304 304 S->D: Decreased level of phosphorylation and Rac-binding ability and important loss of the ability to induce apoptosis 304 304 S->E: Decreased Rac-binding ability | N | |
| 8 | P46109 | Crk-like protein | 303 | 160 160 W->L: Abolishes interaction with DOCK5 | Y | |
| 9 | Q8TEJ3 | E3 ubiquitin-protein ligase SH3RF3 | 882 | 73 73 C->A: Significant reduction in autoubiquitination when associated with A-75 75 75 H->A: Significant reduction in autoubiquitination when associated with A-73 403 403 I->N: Significant loss of interaction with RAC1 alone or when associated with P-404 and A-406 404 404 S->P: Reduced JNK activation alone or when associated with N-403 and A-406 406 406 P->A: Significant loss of interaction with RAC1 when associated with N-403 and P-404 | N | |
| 10 | P16333 | Cytoplasmic protein NCK1 | 377 | 38 38 W->K: Small decrease in RASA1-binding when associated with K-143 and K-229 143 143 W->K: No effect on RASA1-binding when associated with K-38 and K-229 229 229 W->K: Small decrease in RASA1-binding when associated with K-38 and K-229 308 308 R->K: No effect on RASA1-binding | Y | |
| 11 | O43639 | Cytoplasmic protein NCK2 | 380 | 148 148 W->K: Abolishes interaction with DOCK1 234 234 W->K: Abolishes interaction with DOCK1 | Y | |
| 12 | Q15811 | Intersectin-1 | 1721 | 1369 1369 M->L: Decreases specificity for CDC42 when associated with I-1376 1376 1376 L->I: Decreases specificity for CDC42 when associated with L-1369 | N | |
| 13 | Q6ZMT1 | SH3 and cysteine-rich domain-containing protein 2 | 411 | 306 306 Q->L: Mildly decreased affinity for CACNA1S 329 329 W->S: Loss of interaction with CACNA1S 347 347 Q->I: No effect on the structure of the two SH3 domains | Y | |
| 14 | O60229 | Kalirin | 2985 | 2712 2712 K->A: Loss of autophosphorylation | N | |
| 15 | P14598 | Neutrophil cytosol factor 1 | 390 | 43 43 R->Q: Reduces affinity for membranes enriched in phosphatidylinositol 3,4-bisphosphate 90 90 R->A: Reduces affinity for membranes enriched in phosphatidylinositol 3,4-bisphosphate 263 263 W->R: Abolishes autoinhibition and promotes phospholipid binding 303 303 S->E: Abolishes autoinhibition and promotes phospholipid binding when associated with E-304 E-328 E-359 and E-370 304 304 S->E: Abolishes autoinhibition and promotes phospholipid binding when associated with E-303 E-328 E-359 and E-370 328 328 S->E: Abolishes autoinhibition and promotes phospholipid binding when associated with E-303 E-304 E-359 and E-370 359 359 S->E: Abolishes autoinhibition and promotes phospholipid binding when associated with E-303 E-304 E-328 and E-370 370 370 S->E: Abolishes autoinhibition and promotes phospholipid binding when associated with E-303 E-304 E-328 and E-359 | Y | |
| 16 | Q5TCZ1 | SH3 and PX domain-containing protein 2A | 1133 | 42 42 R->A: Loss of binding to (PtdIns(3)P) and (PtdIns(3,4)P2) 93 93 R->A: Loss of binding to (PtdIns(3)P) and (PtdIns(3,4)P2) | N | |
| 17 | Q9P0V3 | SH3 domain-binding protein 4 | 963 | 92 92 W->A: Loss of function | Y | |
| 18 | O75962 | Triple functional domain protein | 3097 | 1299 1299 E->A: 50% decrease in nucleotide exchange activity 1303 1303 T->A: 40% decrease in nucleotide exchange activity 1389 1389 N->A: No change in nucleotide exchange activity 1426 1426 V->A: 90% decrease in nucleotide exchange activity 1427 1427 Q->A: 80% decrease in nucleotide exchange activity 1428 1428 R->A: 80% decrease in nucleotide exchange activity 1430 1430 T->A: 80% decrease in nucleotide exchange activity 1431 1431 K->A: Loss of nucleotide exchange activity 1434 1434 L->A: 40% decrease in nucleotide exchange activity 1437 1437 K->A: No change in nucleotide exchange activity 1438 1438 E->A: 30% decrease in nucleotide exchange activity | N | |